Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Vera Therapeutics, Inc. (VERA) had Normalized Income after Taxes of $-76.53M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-76.53M |
|
-- |
|
-- |
|
$80.14M |
|
$-80.14M |
|
$3.61M |
|
$-76.53M |
|
$-76.53M |
|
$-76.53M |
|
$-76.53M |
|
$-76.53M |
|
|
Normalized Income after Taxes |
$-76.53M |
$-80.14M |
|
$-81.76M |
|
63.79M |
|
63.79M |
|
$-1.20 |
|
$-1.20 |
|
| Balance Sheet Financials | |
$571.35M |
|
$1.15M |
|
$7.17M |
|
$578.53M |
|
$33.55M |
|
$74.46M |
|
$76.70M |
|
$110.25M |
|
$468.28M |
|
$468.28M |
|
$468.28M |
|
63.82M |
|
| Cash Flow Statement Financials | |
$-109.20M |
|
$43.86M |
|
$21.82M |
|
$92.65M |
|
$49.12M |
|
$-43.52M |
|
$17.22M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
17.03 |
|
-- |
|
-- |
|
0.14 |
|
0.16 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-109.60M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-16.34% |
|
-16.34% |
|
-13.23% |
|
-14.10% |
|
$7.34 |
|
$-1.72 |
|
$-1.71 |
|